To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
Here is a small sampling of Gulf War Illness studies by title:
Ready to become a subscriber? Go to our PRICING page. Want to learn more about Endocannabinoid Medicine? Buy a book.
A clear, science-based guide to working with the endocannabinoid system for whole-body balance.
Buy Book
A practical, evidence-based guide to using cannabis and cannabinoids for chronic pain.
Buy BookTo see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
Here is a small sampling of Gulf War Illness studies by title:
Ready to become a subscriber? Go to our PRICING page. Want to learn more about Endocannabinoid Medicine? Buy a book.
A clear, science-based guide to working with the endocannabinoid system for whole-body balance.
Buy Book
A practical, evidence-based guide to using cannabis and cannabinoids for chronic pain.
Buy BookGulf War Illness (GWI) is a long-lasting condition affecting veterans of the 1990–1991 Gulf War. Rather than damaging a single organ, it disrupts how multiple body systems work together—particularly those that regulate communication between the brain, immune system, stress-response systems, and the gut.
Research indicates that GWI is associated with functional dysregulation across the nervous, immune, autonomic, and endocrine systems. These systems may remain structurally intact yet become locked into maladaptive signaling patterns, leading to difficulty recovering from stress and a nervous system that remains on high alert long after the original exposures have ended.
This framework aligns with patient experience: symptoms may appear in different organs, but they share a common theme, reduced regulatory flexibility, and impaired recovery. The body feels unable to fully reset.
While the precise causes of GWI are still under investigation, exposure to pyridostigmine bromide (PB) is considered a major contributing factor. Emerging evidence suggests that PB may induce long-lasting, latent changes in neuroimmune signaling, particularly within the gut–brain axis, by altering how endogenous lipid mediators such as palmitoylethanolamide (PEA) regulate inflammation and neural communication. These changes involve shifts in endocannabinoid signaling, TRPV1 activity, and PPARα-mediated anti-inflammatory pathways, helping explain why symptoms can persist or re-emerge long after exposure.
Importantly, Gulf War Illness is now recognized as a real, biologically grounded medical condition, not a psychological disorder or a failure of coping, as it was often mischaracterized in the past. Its development likely reflects a convergence of chemical exposures, physiological stress, and individual vulnerability.
What remains consistent is that people with GWI live in bodies that are working harder than normal to maintain balance.
Clinically, this understanding supports a broader approach to care—one that emphasizes restoring regulatory capacity across stress response, immune balance, sleep, pain processing, and neurochemical signaling, rather than focusing narrowly on isolated symptoms.
At its core, Gulf War Illness is best understood as a disorder of system coordination and regulation, not damage to individual parts. Care that respects this systems-level reality is most likely to support meaningful recovery.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.